Sorry, you need to enable JavaScript to visit this website.

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the
Efficacy and Safety of Abrocitinib (PF-04965842) in Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects. A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of Abrocitinib (PF 04965842) in Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects.

Category & Conditions: Skin Diseases and Conditions
Medicine: abrocitinib (PF-04965842)
ClinicalTrials.gov Identifier (NCT): NCT03627767
Protocol ID: B7451014
    Share
PrintDownload
Open Plain Language Summary Result: Click here